European journal of preventive cardiology · 2026
Association between single-pill combination therapy use and blood pressure control in the Systolic Blood Pressure Reduction Intervention Trial: a post hoc analysis.
СтатьяРандомизированное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rao Shreya, Segar Matthew W, Keshvani Neil, Soni Suha, Agarwal Anubha, Huffman Mark D, Hsue Priscilla, Vongpatanasin Wanpen, Ramachandran Vasan, Wang Thomas J, Pandey Ambarish
Аннотация
AIMS: Blood pressure (BP) control remains suboptimal among US patients with hypertension. Single-pill combination (SPC) therapies are commonly used to improve adherence; however, their effectiveness for achieving early and sustained intensive BP control is unclear.
METHODS AND RESULTS: We performed a post hoc analysis of Systolic Blood Pressure Intervention Trial (SPRINT) including 2736 participants propensity matched in a 1:2 ratio to compare effects of SPCs with equivalent multi-pill therapy. The estimated marginal odds of achieving target BP control were derived using generalized linear mixed models with repeated measures (LMMRMs). The association between time-updated SPC use and BP change in short- (≤6 months) and long-term (>6 months) follow-up was assessed with LMMRM and SPC * time interaction term. Multivariable Cox models evaluated the association of SPC use with cardiovascular events and serious adverse events (SAEs). Among SPRINT participants (n = 8623), 9.3% (n = 803) were prescribed SPC at baseline with greater use in the intensive vs. usual care group (5.79 vs. 3.90 per 100 person-months; P-diff < 0.001). Among matched pairs [SPC (n = 912); multi-pill therapy (n = 1824)], SPC use was associated with 22% increased likelihood of achieving target BP by 6 months [odds ratio (95% confidence interval), 1.22 (1.05, 1.42)]. Participants receiving SPCs (vs. multi-pills) experienced more rapid BP reduction in the first 6 months (-2.0 vs. -1.2 mmHg monthly change; P-diff < 0.001). Over long-term follow-up, participants using SPCs achieved significantly lower SBP at each time point. The risk of the primary CV composite endpoint and SAEs were not significantly different between groups.
CONCLUSION: Single-pill combination use resulted in greater likelihood of achieving target BP control and more rapid, sustained BP reduction without an increase in SAEs.
METHODS AND RESULTS: We performed a post hoc analysis of Systolic Blood Pressure Intervention Trial (SPRINT) including 2736 participants propensity matched in a 1:2 ratio to compare effects of SPCs with equivalent multi-pill therapy. The estimated marginal odds of achieving target BP control were derived using generalized linear mixed models with repeated measures (LMMRMs). The association between time-updated SPC use and BP change in short- (≤6 months) and long-term (>6 months) follow-up was assessed with LMMRM and SPC * time interaction term. Multivariable Cox models evaluated the association of SPC use with cardiovascular events and serious adverse events (SAEs). Among SPRINT participants (n = 8623), 9.3% (n = 803) were prescribed SPC at baseline with greater use in the intensive vs. usual care group (5.79 vs. 3.90 per 100 person-months; P-diff < 0.001). Among matched pairs [SPC (n = 912); multi-pill therapy (n = 1824)], SPC use was associated with 22% increased likelihood of achieving target BP by 6 months [odds ratio (95% confidence interval), 1.22 (1.05, 1.42)]. Participants receiving SPCs (vs. multi-pills) experienced more rapid BP reduction in the first 6 months (-2.0 vs. -1.2 mmHg monthly change; P-diff < 0.001). Over long-term follow-up, participants using SPCs achieved significantly lower SBP at each time point. The risk of the primary CV composite endpoint and SAEs were not significantly different between groups.
CONCLUSION: Single-pill combination use resulted in greater likelihood of achieving target BP control and more rapid, sustained BP reduction without an increase in SAEs.